FindTrial
Sign In

Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease

Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003766
Enrollment
Unknown
Registered
2020-08-27
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet's Disease

Interventions

experimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets
control group:placebo + Thalidomide Tablets

Sponsors

Shanghai Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 16 years; 2. In compliance with the 2013 International Behets disease diagnostic criteria; 3. The patient or his family members signed the informed consent.

Exclusion criteria

Exclusion criteria: Exclude other autoimmune diseases (systemic lupus erythematosus, Crohns disease, ulcerative colitis), exclude infection-related diseases (syphilis, active Tuberculosis), exclude the tumor.

Design outcomes

Primary

MeasureTime frame
C reactive protein;Erythrocyte sedimentation rate ;Interleukin-10;Interleukin-4;Interleukin-6;Tumor necrosis factor Tumor a necrosis factor a;—

Countries

China

Contacts

Public ContactChenWeiwei

Shanghai Traditional Chinese Medicine Hospital

daphneww@126.com+86 18116013386

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026